GRFS - グリフォルス (Grifols S.A.)

GRFSのニュース

   Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment  2019/12/12 14:24:00 PR Newswire
BARCELONA, Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20%…
   Global Blood Grouping Reagents Market 2020-2024 | Evolving Opportunities with DIAGAST and Grifols SA | Technavio  2019/12/02 15:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #Biotechnology--Global blood grouping reagents market is poised to grow by USD 443.28 million during 2020-2024 at a CAGR of over 10% during the forecast period.
   The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   GRIFOLS S A/S (NASDAQ:GRFS) Stock Rating Upgraded by Zacks Investment Research  2019/11/16 20:10:37 Modern Readers
GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
   Hedge Funds Have Never Been This Bullish On Grifols SA (GRFS)  2019/10/11 15:15:22 ACI Information Group
We can judge whether Grifols SA (NASDAQ:GRFS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their
   Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment  2019/12/12 14:24:00 PR Newswire
BARCELONA, Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20%…
   Global Blood Grouping Reagents Market 2020-2024 | Evolving Opportunities with DIAGAST and Grifols SA | Technavio  2019/12/02 15:00:00 Business Wire
LONDON--(BUSINESS WIRE)-- #Biotechnology--Global blood grouping reagents market is poised to grow by USD 443.28 million during 2020-2024 at a CAGR of over 10% during the forecast period.
   The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen  2019/11/27 12:26:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ardelyx Inc (NASDAQ: ARDX ) ( announced a research collaboration with Japan's Kyowa Kirin and an investment in the company by the latter) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(reacted to its full-year results) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) ChemoCentryx Inc (NASDAQ: CCXI )( announced positive late-stage results for rare inflammation disease drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Global Blood Therapeutics Inc (NASDAQ: GBT )(announced FDA nod for sickle cell disease drug) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co., Inc. (NYSE: MRK )(Keytruda was approved in China as a first-line treatment for lung cancer, in combination with chemotherapy) Molecular Templates Inc (NASDAQ: …
   GRIFOLS S A/S (NASDAQ:GRFS) Stock Rating Upgraded by Zacks Investment Research  2019/11/16 20:10:37 Modern Readers
GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
   Hedge Funds Have Never Been This Bullish On Grifols SA (GRFS)  2019/10/11 15:15:22 ACI Information Group
We can judge whether Grifols SA (NASDAQ:GRFS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their

calendar